-
Cost-Consequence of Incorporating Single-Operator Direct Visualization Cholangioscopy in the Diagnosis of Indeterminate Biliary Strictures in Saudi Arabia
Sep 9, 2025, 16:22 PM -
Common Criticism of Patient-Reported Outcomes (PRO) in Health Technology Assessments (HTA) by the Institute for Quality and Efficiency in Healthcare (IQWiG) in Breast Cancer and Non-Small Cell Lung Cancer (NSCLC)
Sep 9, 2025, 16:22 PM -
Measuring the Elephant in the Room: Quantifying Legal Barriers to AI Processing of Full?Text in Systematic Reviews
Sep 9, 2025, 16:22 PM -
Impact of Nirsevimab on the Health Burden and Costs of Respiratory Syncytial Virus (RSV) in the Infant Population From the Healthcare System in Argentina
Sep 9, 2025, 16:22 PM -
Burden of Illness Among Patients With Transfusion Dependent Beta-Thalassemia in Spain: A Registry-Based Study
Sep 9, 2025, 16:22 PM -
Addressing the Inherent Challenges of the French National Claims Database (SNDS) Through Algorithms to Identify Patients With Diffuse Large B-cell Lymphoma (DLBCL) and Their Chemotherapy Treatments
Sep 9, 2025, 16:22 PM -
Using Structured Expert Elicitation to Estimate Long-Term Organ Damage Risk in an Ultrarare Condition: A STEER Case Study
Sep 9, 2025, 16:22 PM -
Development of Cardiovascular Risk Equations: Integrating Clinical Expertise With Data From the SELECT Trial
Sep 9, 2025, 16:22 PM -
Health Equity in Economic Analyses of Person-Centered Care: A Systematic Review
Sep 9, 2025, 16:22 PM -
The Estimation of the Prevalent Presymptomatic Type 1 Diabetes Population in Germany Using a Patient Funnel Model
Sep 9, 2025, 16:22 PM -
Occurrence of Exacerbations and Mortality in High-Risk Chronic Obstructive Pulmonary Disease Patients While on Treatment With Dual or Triple Inhaled Therapy: Results From the SIRIUS Observational Study in the US
Sep 9, 2025, 16:22 PM -
Worth Their Weight? Cost-Effectiveness and Access Decisions for GLP-1 and GIP/GLP-1 Therapies
Sep 9, 2025, 16:22 PM -
Pragmatic Advice to Improve Assessment Schedule of Preference-Based Measures of Health to Estimate Utilities in Clinical Trials
Sep 9, 2025, 16:22 PM -
Health Economic Evaluation Model for Breast Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)
Sep 9, 2025, 16:22 PM -
CDF or CDFoe: How Has the Cancer Drugs Fund Impacted Access to Atezolizumab for Patients With Non-Small Cell Lung Cancer in the Adjuvant Setting?
Sep 9, 2025, 16:22 PM -
Assessing Accuracy of Unsupervised Large Language Model Tools for Identifying Key Criteria Supporting Abstract Screening
Sep 9, 2025, 16:22 PM -
Canadian HTA Decisions (2020-2023): Comparing CDA-AMC and INESSS Recommendations on Drug Reimbursement
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Etrasimod, Ozanimod, and Adalimumab Compared to Infliximab in Treatment-Naive Patients With Moderate to Severe Ulcerative Colitis
Sep 9, 2025, 16:22 PM -
Review of CEESP ICERs for Orphan and Nonorphan Treatments in France, 2024-2025
Sep 9, 2025, 16:22 PM -
Enhancing Patient Involvement in European Health Technology Assessment (HTA): From Inconsistent National Practices to Systematic Engagement in Joint Clinical Assessments
Sep 9, 2025, 16:22 PM
